|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
28
|
|
pubmed:dateCreated |
2008-9-30
|
|
pubmed:abstractText |
Diffuse large B-cell lymphoma (DLBCL) includes at least two prognostically important subtypes (ie, germinal center B-cell-like [GCB] and activated B-cell-like [ABC] DLBCL), which initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining. However, with the addition of rituximab to standard chemotherapy, the prognostic significance of this subclassification of DLBCL is unclear.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Mitoxantrone,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ArmitageJames OJO,
pubmed-author:BiermanPhilip JPJ,
pubmed-author:BociekR GregoryRG,
pubmed-author:ChanWing CWC,
pubmed-author:ChoiWilliam W LWW,
pubmed-author:FuKaiK,
pubmed-author:GreinerTimothy CTC,
pubmed-author:HansChristine PCP,
pubmed-author:PerryKyle DKD,
pubmed-author:ShiXinlanX,
pubmed-author:SmithLynette MLM,
pubmed-author:VoseJulie MJM,
pubmed-author:WeisenburgerDennis DDD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4587-94
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18662967-Adult,
pubmed-meshheading:18662967-Aged,
pubmed-meshheading:18662967-Aged, 80 and over,
pubmed-meshheading:18662967-Antibodies, Monoclonal,
pubmed-meshheading:18662967-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18662967-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18662967-Chi-Square Distribution,
pubmed-meshheading:18662967-Cyclophosphamide,
pubmed-meshheading:18662967-Disease Progression,
pubmed-meshheading:18662967-Doxorubicin,
pubmed-meshheading:18662967-Female,
pubmed-meshheading:18662967-Germinal Center,
pubmed-meshheading:18662967-Humans,
pubmed-meshheading:18662967-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:18662967-Male,
pubmed-meshheading:18662967-Middle Aged,
pubmed-meshheading:18662967-Mitoxantrone,
pubmed-meshheading:18662967-Prednisolone,
pubmed-meshheading:18662967-Prednisone,
pubmed-meshheading:18662967-Prognosis,
pubmed-meshheading:18662967-Proportional Hazards Models,
pubmed-meshheading:18662967-Survival Rate,
pubmed-meshheading:18662967-Treatment Outcome,
pubmed-meshheading:18662967-Vincristine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
|
|
pubmed:affiliation |
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
